Fezakinumab
Alternative Names: ILV-094; PF-5212367Latest Information Update: 05 Nov 2023
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antirheumatics; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Interleukin-22 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis; Rheumatoid arthritis
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Canada (IV)
- 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Canada (SC)
- 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Hong Kong (IV)